These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26679247)

  • 1. Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
    Palombi L; Pirillo MF; Marchei E; Jere H; Sagno JB; Luhanga R; Floridia M; Andreotti M; Galluzzo CM; Pichini S; Mwenda R; Mancinelli S; Marazzi MC; Vella S; Liotta G; Giuliano M
    J Antimicrob Chemother; 2016 Apr; 71(4):1027-30. PubMed ID: 26679247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
    Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC;
    Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.
    Floridia M; Liotta G; Andreotti M; Galluzzo CM; Amici R; Jere H; Sagno JB; Marazzi MC; Buonomo E; Scarcella P; Mancinelli S; Vella S; Giuliano M; Palombi L
    J Antimicrob Chemother; 2016 Nov; 71(11):3206-3211. PubMed ID: 27494909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
    J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009.
    Schwartz SR; Kumwenda N; Kumwenda J; Chen S; Mofenson LM; Taylor AW; Fowler MG; Taha TE
    Matern Child Health J; 2016 Mar; 20(3):542-9. PubMed ID: 26525557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
    Boivin MJ; Maliwichi-Senganimalunje L; Ogwang LW; Kawalazira R; Sikorskii A; Familiar-Lopez I; Kuteesa A; Nyakato M; Mutebe A; Namukooli JL; Mallewa M; Ruiseñor-Escudero H; Aizire J; Taha TE; Fowler MG
    Lancet HIV; 2019 Aug; 6(8):e518-e530. PubMed ID: 31122797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
    Mancinelli S; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Amici R; Pirillo MF; Scarcella P; Marazzi MC; Vella S; Palombi L; Giuliano M
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):737-42. PubMed ID: 27067142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.
    Waitt C; Olagunju A; Nakalema S; Kyohaire I; Owen A; Lamorde M; Khoo S
    J Antimicrob Chemother; 2018 Apr; 73(4):1013-1019. PubMed ID: 29309634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.
    Lartey M; Kenu E; Lassey A; Ntumy M; Ganu V; Sam M; Boamah I; Gilani FS; Yang H; Burch GM; Norman J; Peloquin CA; Kwara A
    Clin Ther; 2020 Sep; 42(9):1818-1825. PubMed ID: 32811669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety.
    Palombi L; Pirillo MF; Andreotti M; Liotta G; Erba F; Sagno JB; Maulidi M; Ceffa S; Jere H; Marchei E; Pichini S; Galluzzo CM; Marazzi MC; Vella S; Giuliano M
    Antivir Ther; 2012; 17(8):1511-9. PubMed ID: 22910456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
    Mirochnick M; Thomas T; Capparelli E; Zeh C; Holland D; Masaba R; Odhiambo P; Fowler MG; Weidle PJ; Thigpen MC
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1170-6. PubMed ID: 19114673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
    Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
    PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
    Lamorde M; Schapiro JM; Burger D; Back DJ
    AIDS; 2014 Nov; 28(17):2551-63. PubMed ID: 25574958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
    Palombi L; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Luhanga R; Mancinelli S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2015 Oct; 70(10):2881-4. PubMed ID: 26111981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
    Palombi L; Marazzi MC; Voetberg A; Magid NA
    AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
    Price AJ; Kayange M; Zaba B; Chimbwandira FM; Jahn A; Chirwa Z; Dasgupta AN; Katundu C; Saul JL; Glynn JR; Koole O; Crampin AC
    Sex Transm Infect; 2014 Jun; 90(4):309-14. PubMed ID: 24714445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
    Kapito-Tembo AP; Bauleni A; Wesevich A; Ongubo D; Hosseinipour MC; Dube Q; Mwale P; Corbett A; Mwapasa V; Phiri S
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):81-90. PubMed ID: 33027153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
    Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
    Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.